EFZO-FIT, a Phase 3 clinical study testing efzofitimod for pulmonary sarcoidosis, failed to meet its main goal of significantly reducing the need for corticosteroids among people with the rare inflammatory disease. […] The post Efzofitimod misses main goal in large pulmonary sarcoidosis trial appeared first on Sarcoidosis News.
